(Q42798110)

7 November 2017

PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs (English)

1 reference

7 November 2017

R L Ross

1

1 reference

7 November 2017

J M Askham

series ordinal

2

1 reference

7 November 2017

M A Knowles

series ordinal

3

1 reference

7 November 2017

language of work or name

English

0 references

publication date

19 March 2012

1 reference

7 November 2017

1 reference

7 November 2017

32

1 reference

7 November 2017

768-776

1 reference

7 November 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2012.87

7 November 2017

0 references

cites work

Oncogenic PI3K and its role in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Rare cancer-specific mutations in PIK3CA show gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Functional analysis of PIK3CA gene mutations in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Knockin of mutant PIK3CA activates multiple oncogenic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

A frequent kinase domain mutation that changes the interaction between PI3K and the membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Phosphoinositide 3-kinases in cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

The green tea compound, (-)-epigallocatechin-3-gallate downregulates N-cadherin and suppresses migration of bladder carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Functional differences between two classes of oncogenic mutation in the PIK3CA gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Mutation of the PIK3CA gene in ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

Short hairpin RNA system to inhibit human p16 in squamous cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.87

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.87

1 reference

Dimensions Publication ID

7 November 2017

0 references

1 reference